In Japan, PIVLAZ™ (clazosentan) 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing. With the positive listing decision, Japan’s National Health Insurance system has recognized that the clinical efficacy demonstrated with PIVLAZ fulfills an important medical […]